<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819843</url>
  </required_header>
  <id_info>
    <org_study_id>16-224</org_study_id>
    <nct_id>NCT02819843</nct_id>
  </id_info>
  <brief_title>A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors</brief_title>
  <official_title>A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this phase II clinical study is to test the good and bad effects of T-VEC&#xD;
      (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with&#xD;
      melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response</measure>
    <time_frame>16 weeks</time_frame>
    <description>Overall subject level response is defined as partial or complete (&gt;50% or greater decrease in largest lesion) by the modified World Health Organization (mWHO) criteria, and will include measurements of tumor size by CT component of PET/CT, and clinically by digital photography.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Melanoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TALIMOGENE LAHERPAREPVEC (TVEC)</intervention_name>
    <arm_group_label>Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy</arm_group_label>
    <arm_group_label>Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiotherapy</intervention_name>
    <arm_group_label>Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman ≥ 18 years old&#xD;
&#xD;
          -  Life expectancy &gt; 4 months&#xD;
&#xD;
          -  Histopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor&#xD;
             malignancy&#xD;
&#xD;
          -  Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis not suitable&#xD;
             for surgical resection&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&#xD;
&#xD;
          -  Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis that is&#xD;
             amenable to injection and irradiation and &gt; 10 mm in longest dimension&#xD;
&#xD;
             ° Cutaneous metastasis in a region of previous radiation therapy is amenable to&#xD;
             radiation therapy as part of this protocol if at least 6 months has elapsed since&#xD;
             prior radiotherapy and the dose of radiotherapy previously administered did not exceed&#xD;
             an equivalent dose of 60 Gy in 2 Gy equivalent fractions at the skin surface (using&#xD;
             linear-quadratic modeling with alpha/beta=11.5)&#xD;
&#xD;
          -  Metastasis that is &gt; 10 mm in longest dimensionor exhibits radiotracer uptake&#xD;
             consistent with metastasis on PET/CT&#xD;
&#xD;
          -  Adequate coagulation function (platelet count &gt;50 k/mcL, international normalized&#xD;
             ratio of &lt; 1.5)&#xD;
&#xD;
          -  Resolution or stabilization of clinically significant adverse events from prior&#xD;
             therapy&#xD;
&#xD;
          -  Able to provide valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active herpetic skin lesions or prior complications of HSV-1 infection (such as&#xD;
             herpetic keratitis, herpetic encephalitis)&#xD;
&#xD;
          -  Receipt of a therapeutic anticoagulant&#xD;
&#xD;
          -  Receipt of live vaccine within 28 days of planned first dose of TVEC&#xD;
&#xD;
          -  Receipt of another cancer therapy (targeted therapy, chemotherapy, investigational&#xD;
             therapy, immunotherapy, radiotherapy or surgery) which is yielding an overall response&#xD;
             (by response criteria in this study)&#xD;
&#xD;
             ° Patients with stable or progressing disease (as determined by at least 2 consecutive&#xD;
             assessments at 6-week interval) can continue to receive the same therapy during&#xD;
             treatment as part of this protocol&#xD;
&#xD;
          -  History of symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's&#xD;
             disease, ulcerative colitis) requiring systemic treatment (for example corticosteroids&#xD;
             or immunosuppressants); replacement therapy (for example, thyroxine, insulin) is not&#xD;
             considered a systemic treatment&#xD;
&#xD;
          -  History of high grade (CTCAE ≥ Grade 3) immune mediated adverse event from prior&#xD;
             cancer immunotherapy&#xD;
&#xD;
          -  History of CTCAE ≥ Grade 2 immune mediated endocrinopathy from prior cancer&#xD;
             immunotherapy&#xD;
&#xD;
          -  Intermittent or chronic use of oral or intravenous antiherpetic drug (such as&#xD;
             acyclovir)&#xD;
&#xD;
          -  Active or chronic hepatitis B or C infection&#xD;
&#xD;
             ° Previously infected, with evidence of immunity and no evidence of active hepatitis&#xD;
             is not an exclusion criterion&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known leukemia or lymphoma&#xD;
&#xD;
          -  Common variable immunodeficiency&#xD;
&#xD;
          -  Patients requiring chronic high dose immunosuppressants including steroids (prednisone&#xD;
             daily equivalent of ≥ 10 mg)&#xD;
&#xD;
          -  Known severe congenital or acquired cellular or humoral immunodeficient or&#xD;
             immunocompromised patients&#xD;
&#xD;
          -  High likelihood of protocol non-compliance (in opinion of investigator)&#xD;
&#xD;
          -  Woman of childbearing potential unwilling to use effective contraception during&#xD;
             protocol treatment and for 3 months after last dose of Talimogene Laherparepvec&#xD;
&#xD;
          -  Woman of childbearing potential that is pregnant or breast-feeding, or planning to&#xD;
             become pregnant or breast-feed during protocol treatment and for 3 months after last&#xD;
             dose of Talimogene Laherparepvec&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-VEC (Talimogene Laherparepvec)</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>16-224</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talimogene laherparepvec</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

